Development of daptomycin-susceptible, methicillin-resistant staphylococcus aureus pneumonia during high-dose daptomycin therapy

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1286-1287

  Koplowicz, Yelena B ^a   Schwartz, Brian S ^b   Guglielmo, Joseph B ^a  

^a Department of Clinical Pharmacy ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; BLOODSTREAM INFECTION; CASE REPORT; DRUG FEVER; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; ENTEROCOCCAL INFECTION; HUMAN; KIDNEY TRANSPLANTATION; LETTER; LIVER TRANSPLANTATION; LUNG LAVAGE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; DAPTOMYCIN; HUMANS; LUNG; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PNEUMONIA, STAPHYLOCOCCAL; TOMOGRAPHY; UNITED STATES;

EID: 70349929237     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605690     Document Type: Letter

References (4)

1. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004;38:994-1000.
2. Cubicin (daptomycin) [package insert]. Lexington, MA: Cubist Pharmaceuticals, 2008.
3. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008;46:1142-1151 (Pubitemid 351589895)
4. Silverman JA, Mortin LI, VanPraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005;191:2149-2152 (Pubitemid 40800587)